A recent study demonstrated the therapeutic potential of an anti-CEACAM6 monoclonal antibody by increasing the anoikis sensitivity in lung adenocarcinoma20; however, the use of RNA interference (RNAi)-based therapy to inhibit CEACAM6 in lung cancer has not been investigated. This evidence concerns the gene CEACAM6 and lung carcinoma.